Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
Ajai Chari, Cyrille Touzeau, Carolina Schinke...
https://pubmed.ncbi.nlm.nih.gov/40090350/Actively Recruiting
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
510
Participants Needed
78
Research Sites
91 weeks
Total Duration
Researchers are evaluating the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma who have received multiple prior treatments. This Phase 2 study focuses on determining the recommended doses and assessing the treatment in different participant groups based on previous therapies received. The study is sponsored by Janssen Research & Development, LLC and aims to provide new treatment options for this condition. Participants are divided into five cohorts based on their treatment history, including exposure to T cell redirection therapies and prior medications. Talquetamab is administered subcutaneously at recommended Phase 2 doses, with dosing schedules including biweekly administration in some cohorts. All participants will transition to an open-label extension phase to continue receiving the study treatment, followed by a long-term extension phase upon sponsor approval. Throughout the study, participants will undergo regular assessments to measure treatment response, safety, and tolerability. These include evaluations of overall response rate, duration of response, progression-free survival, quality of life questionnaires, laboratory tests, and monitoring for adverse events. The study duration includes follow-up to approximately 2 years and 10 months. Talquetamab concentrations and antibody presence will also be monitored to understand treatment effects and immune response.
CONDITIONS
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
S
Study Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Janssen Research & Development, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Talquetamab (trial) | Physician’s choice (real‑world) |
|---|---|---|
| What it is | A GPRC5D‑targeting bispecific antibody (Talquetamab) given subcutaneously in various dosing cohorts until disease progression | Standard regimens selected by clinicians in real‑world practice for patients with triple‑class exposed relapsed/refractory multiple myeloma |
| Role in trial | Investigational monotherapy tested in all trial cohorts | Not part of the MonumenTAL‑1 trial, shown here only for clinical context |
| Primary use | Treatment of relapsed or refractory multiple myeloma after prior lines of therapy | Current practice for treating heavily pretreated, triple‑class exposed relapsed/refractory multiple myeloma |
| How it is given or performed | Subcutaneous talquetamab administered per dosing cohort continuously until progression | Varies by regimen as per treating clinician’s choice in routine practice |
| Evidence status | MonumenTAL‑1 results ongoing; early and updated analyses show superiority over real‑world outcomes for progression‑free survival, overall survival and time to next treatment | Historically poor outcomes observed in triple‑class exposed population in real‑world data |
| Important risks | Safety profile being defined; risks include on‑target off‑tumor effects and cytokine‑release syndrome as reported in MonumenTAL‑1 | Depends on regimen; real‑world treatments can have regimen‑specific toxicity profiles |
| Important limitations | Single‑arm trial design limits direct internal comparison; generalizability to broad practice may be limited by strict eligibility | Real‑world data may be heterogeneous and observational without randomized control |
| Patient impact | Talquetamab treatment associated with improved progression‑free and overall survival compared with historical real‑world outcomes | Standard care outcomes are generally inferior in triple‑class exposed patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several years, including extension phases
Participants receive talquetamab subcutaneously according to their assigned cohort's dosing schedule until disease progression. Some participants receive tocilizumab prophylaxis for cytokine release syndrome. Participants transition to open-label extension and long-term extension phases to continue treatment as approved.
Regular visits as scheduled by the study
Duration - Up to 2 years and 10 months
Participants are monitored for treatment response, safety, and quality of life. Assessments include laboratory tests, questionnaires, and monitoring for adverse events throughout the study duration.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Ajai Chari, Cyrille Touzeau, Carolina Schinke...
https://pubmed.ncbi.nlm.nih.gov/40090350/Hermann Einsele, Philippe Moreau, Nizar Bahlis...
https://pubmed.ncbi.nlm.nih.gov/41313549/Carolina Schinke, Paula Rodríguez-Otero, Niels W C J van de Donk...
https://pubmed.ncbi.nlm.nih.gov/42803498/Niels W C J van de Donk, Ajai Chari, Thomas Martin...
https://pubmed.ncbi.nlm.nih.gov/41036677/Leo Rasche, Carolina Schinke, Cyrille Touzeau...
https://pubmed.ncbi.nlm.nih.gov/42561120/Donna Catamero, Chloe Ray, Kiah Purcell...
https://pubmed.ncbi.nlm.nih.gov/39155155/Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk...
https://pubmed.ncbi.nlm.nih.gov/40864183/Carolina Schinke, Cyrille Touzeau, Albert Oriol...
https://pubmed.ncbi.nlm.nih.gov/42299486/Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami...
https://pubmed.ncbi.nlm.nih.gov/41405810/Ajai Chari, Cyrille Touzeau, Jesus G Berdeja...
https://pubmed.ncbi.nlm.nih.gov/42669079/Janssen Research & Development, LLC
Lead Sponsor